Skip to main content
. 2021 May 19;17(11):e1728–e1737. doi: 10.1200/OP.20.01050

FIG 2.

FIG 2.

Annual (year-by-year) prevalence of systemic therapy and ICI use among patients with cancer in Western Washington in the last 30 days of life between 2007 and 2018, Cancer Surveillance System, and Linked Pharmacy Claims. HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitor; NSCLC, non–small-cell lung cancer; RCC, renal cell carcinoma.